Dr. Juan Antonio Navarro Langa

Emerging Investigator
Research Group on Cellular and Organic Physiopathology of Oxidative Stress

Presentation

Dr. Juan Antonio Navarro Langa
Emerging
Investigator
Dr. Juan Antonio Navarro Langa

juan.a.navarro@uv.es

Publications
Phosphorylated resveratrol as a protein aggregation suppressor in vitro and in vivo. Mehringer J, Navarro J, Touraud D, Schneuwly S, Kunz W. Rsc Chemical Biology. 2022 Jan 4;3(2):250-260. doi: 10.1039/d1cb00220a. PMID: 35360889

Rabphilin silencing causes dilated cardiomyopathy in a Drosophila model of nephrocyte damage. Selma-Soriano E, Casillas-Serra C, Artero R, Llamusi B, Navarro J, Redon J. Scientific Reports. 2021 Jul 27;11(1):15287. doi: 10.1038/s41598-021-94710-7. PMID: 34315987

Projects
Reference: PI22/00507
Title: Reposicionamiento de fármacos como tratamiento para la enfermedad de Huntington y la ataxia espinocerebelosa de tipo 3. Estudios en cultivos primarios de pacientes y en modelos animales transgénicos.
Funding body: Instituto de Salud Carlos III – Cofinanciado FEDER
Principal Investigator: Federico V. Pallardó Calatayud, Juan Antonio Navarro Langa
Duration: 2023 – 2025
Total budget: 147.620,00 €
Reference: 2021095290
Title: Intracellular iron deposits in a Drosophila Model of Friedreich´s Ataxia
Funding body: Center of Excellence ALBA synchrotron
Principal Investigator: Juan Navarro Langa
Duration: 2022 – 2022
Total budget: 51.471 €
Reference: AP-2021-014
Title: FlyAvatar: Drosophila melanogaster como herramienta de diagnóstico molecular para la Paraparesia Espástica Hereditaria 7 (HSP7)
Funding body: Universidad de Valencia – INCLIVA
Principal Investigator: Mª José Martínez Sebastián, Juan Antonio Navarro Langa
Duration: 2021 – 2022
Total budget: 4.750 €
Reference: CDEI0420C
Title: Plan GenT: Drosophila melanogaster as model to study the impact of ferroptosis in Friedreich´s Ataxia
Funding body: Conselleria de Sanidad
Principal Investigator: Juan Navarro Langa
Duration: 2020 – 2023
Total budget: 246.500 €